UA76939C2 - MUTATIONS eNOS HELPFUL FOR GENOTHERAPY AND THERAPEUTIC SCREENING - Google Patents
MUTATIONS eNOS HELPFUL FOR GENOTHERAPY AND THERAPEUTIC SCREENING Download PDFInfo
- Publication number
- UA76939C2 UA76939C2 UA2001107249A UA2001107249A UA76939C2 UA 76939 C2 UA76939 C2 UA 76939C2 UA 2001107249 A UA2001107249 A UA 2001107249A UA 2001107249 A UA2001107249 A UA 2001107249A UA 76939 C2 UA76939 C2 UA 76939C2
- Authority
- UA
- Ukraine
- Prior art keywords
- residue
- polypeptide
- human
- pmo5
- activity
- Prior art date
Links
- 238000012216 screening Methods 0.000 title abstract description 3
- 230000035772 mutation Effects 0.000 title description 19
- 230000001225 therapeutic effect Effects 0.000 title description 6
- 230000000694 effects Effects 0.000 claims abstract description 80
- 238000000034 method Methods 0.000 claims abstract description 80
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 80
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 64
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 52
- 230000026731 phosphorylation Effects 0.000 claims abstract description 49
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 48
- 229920001184 polypeptide Polymers 0.000 claims abstract description 48
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 44
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 44
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 38
- 230000001419 dependent effect Effects 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 230000002950 deficient Effects 0.000 claims abstract description 10
- 208000037803 restenosis Diseases 0.000 claims abstract description 7
- 206010019280 Heart failures Diseases 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 107
- 238000004519 manufacturing process Methods 0.000 claims description 62
- 241000282414 Homo sapiens Species 0.000 claims description 60
- 230000014509 gene expression Effects 0.000 claims description 38
- 101000702718 Homo sapiens Phosphatidylcholine:ceramide cholinephosphotransferase 1 Proteins 0.000 claims description 37
- 235000004400 serine Nutrition 0.000 claims description 36
- 241000283690 Bos taurus Species 0.000 claims description 35
- 102100030919 Phosphatidylcholine:ceramide cholinephosphotransferase 1 Human genes 0.000 claims description 35
- 239000013598 vector Substances 0.000 claims description 35
- 230000001965 increasing effect Effects 0.000 claims description 34
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 32
- 108700019146 Transgenes Proteins 0.000 claims description 32
- 241000700159 Rattus Species 0.000 claims description 29
- 102000004316 Oxidoreductases Human genes 0.000 claims description 28
- 108090000854 Oxidoreductases Proteins 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 241000701161 unidentified adenovirus Species 0.000 claims description 19
- 210000002889 endothelial cell Anatomy 0.000 claims description 17
- 230000001404 mediated effect Effects 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 238000011161 development Methods 0.000 claims description 13
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 12
- 235000004279 alanine Nutrition 0.000 claims description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 235000003704 aspartic acid Nutrition 0.000 claims description 10
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 10
- 210000004204 blood vessel Anatomy 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 9
- 235000013922 glutamic acid Nutrition 0.000 claims description 9
- 239000004220 glutamic acid Substances 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- 208000031225 myocardial ischemia Diseases 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 7
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 5
- 229960002173 citrulline Drugs 0.000 claims description 5
- 238000002316 cosmetic surgery Methods 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 230000010076 replication Effects 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 4
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 4
- 230000036262 stenosis Effects 0.000 claims description 4
- 208000037804 stenosis Diseases 0.000 claims description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 3
- 230000030609 dephosphorylation Effects 0.000 claims description 3
- 238000006209 dephosphorylation reaction Methods 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 210000000107 myocyte Anatomy 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 2
- 102000002045 Endothelin Human genes 0.000 claims description 2
- 108050009340 Endothelin Proteins 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 2
- 206010052664 Vascular shunt Diseases 0.000 claims description 2
- 108010051583 Ventricular Myosins Proteins 0.000 claims description 2
- 229950006137 dexfosfoserine Drugs 0.000 claims description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 2
- 102000050044 human SGMS1 Human genes 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 claims description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 2
- 108091035707 Consensus sequence Proteins 0.000 claims 2
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 claims 2
- 108060008487 Myosin Proteins 0.000 claims 1
- 102000003505 Myosin Human genes 0.000 claims 1
- 206010054880 Vascular insufficiency Diseases 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 208000023577 vascular insufficiency disease Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 115
- 102000004169 proteins and genes Human genes 0.000 abstract description 80
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 8
- 238000001415 gene therapy Methods 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 208000019622 heart disease Diseases 0.000 abstract description 2
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 102000055702 human NOS3 Human genes 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 73
- 244000212312 Blighia sapida Species 0.000 description 45
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 27
- 239000011575 calcium Substances 0.000 description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 25
- 102100030497 Cytochrome c Human genes 0.000 description 25
- 108010075031 Cytochromes c Proteins 0.000 description 25
- 229910052791 calcium Inorganic materials 0.000 description 25
- 238000001890 transfection Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 21
- 229940088598 enzyme Drugs 0.000 description 21
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 230000004913 activation Effects 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 108020004511 Recombinant DNA Proteins 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 238000011084 recovery Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 102000000584 Calmodulin Human genes 0.000 description 8
- 108010041952 Calmodulin Proteins 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 241001135569 Human adenovirus 5 Species 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 229920002401 polyacrylamide Polymers 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 6
- -1 alanine Chemical class 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 108010001441 Phosphopeptides Proteins 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 4
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 229940079919 digestives enzyme preparation Drugs 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 210000001105 femoral artery Anatomy 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003355 serines Chemical class 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 230000025033 vasoconstriction Effects 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 3
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CCBICDLNWJRFPO-UHFFFAOYSA-N 2,6-dichloroindophenol Chemical compound C1=CC(O)=CC=C1N=C1C=C(Cl)C(=O)C(Cl)=C1 CCBICDLNWJRFPO-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 208000003890 Coronary Vasospasm Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- QDFHPFSBQFLLSW-KQYNXXCUSA-N adenosine 2'-phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OP(O)(O)=O QDFHPFSBQFLLSW-KQYNXXCUSA-N 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 201000011634 coronary artery vasospasm Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000004218 vascular function Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 2
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 2
- 101150021183 65 gene Proteins 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000726739 Butea Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 241001442234 Cosa Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108091005880 Hemoglobin F Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000796941 Homo sapiens Adenosine kinase Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 1
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 101150104182 MOB2 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108091005647 acylated proteins Proteins 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000015624 blood vessel development Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011141 high resolution liquid chromatography Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229940019331 other antithrombotic agent in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000027849 smooth muscle hyperplasia Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012256 transgenic experiment Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
- C12N9/0075—Nitric-oxide synthase (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12955099P | 1999-04-16 | 1999-04-16 | |
PCT/US2000/009913 WO2000062605A1 (en) | 1999-04-16 | 2000-04-14 | eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING |
Publications (1)
Publication Number | Publication Date |
---|---|
UA76939C2 true UA76939C2 (en) | 2006-10-16 |
Family
ID=22440541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2001107249A UA76939C2 (en) | 1999-04-16 | 2000-04-14 | MUTATIONS eNOS HELPFUL FOR GENOTHERAPY AND THERAPEUTIC SCREENING |
Country Status (25)
Country | Link |
---|---|
US (4) | US6900038B2 (no) |
EP (1) | EP1178722A4 (no) |
JP (1) | JP2002541829A (no) |
KR (1) | KR100737945B1 (no) |
CN (1) | CN100357433C (no) |
AU (2) | AU774010B2 (no) |
BG (1) | BG106051A (no) |
BR (1) | BR0009805A (no) |
CA (1) | CA2369764A1 (no) |
CZ (1) | CZ20013427A3 (no) |
EE (1) | EE200100538A (no) |
HK (1) | HK1046081B (no) |
HR (1) | HRP20010797A2 (no) |
HU (1) | HUP0200799A3 (no) |
IL (1) | IL145760A0 (no) |
MX (1) | MXPA01010459A (no) |
NO (1) | NO20015008L (no) |
NZ (1) | NZ514305A (no) |
PL (1) | PL351087A1 (no) |
RU (1) | RU2257226C2 (no) |
SK (1) | SK14692001A3 (no) |
UA (1) | UA76939C2 (no) |
WO (1) | WO2000062605A1 (no) |
YU (1) | YU73301A (no) |
ZA (1) | ZA200108463B (no) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100357433C (zh) * | 1999-04-16 | 2007-12-26 | 耶鲁大学 | 可用于基因治疗和治疗性筛选的eNOS突变 |
US7098016B2 (en) | 2002-06-14 | 2006-08-29 | Wisconsin Alumni Research Foundation | Ribonuclease zymogen design |
AU2003263844A1 (en) * | 2002-08-16 | 2004-03-03 | Cardium Therapeutics Inc. | Gene therapy for critical limb ischemia with wild type or mutant enos |
KR20050042788A (ko) * | 2002-08-16 | 2005-05-10 | 쉐링 악티엔게젤샤프트 | 유전자 요법에 유용한 eNOS 돌연변이체 |
GB0226463D0 (en) * | 2002-11-13 | 2002-12-18 | Isis Innovation | Mimicking the athletic heart |
JP4623719B2 (ja) * | 2002-12-02 | 2011-02-02 | アンジェスMg株式会社 | 血管形成依存性症状を治療または予防する方法 |
US7531318B2 (en) | 2004-08-20 | 2009-05-12 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
DE602005024850D1 (de) * | 2004-09-24 | 2010-12-30 | Beth Israel Hospital | Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen |
US7740849B2 (en) * | 2004-09-24 | 2010-06-22 | Beth Israel Deaconess Medical Center | Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders |
JP2009538915A (ja) * | 2006-05-31 | 2009-11-12 | ベス イスラエル ディーコネス メディカル センター | 妊娠の合併症を診断および治療する方法 |
US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
WO2010011607A1 (en) | 2008-07-22 | 2010-01-28 | Promega Corporation | Adp detection based luminescent phosphotransferase or atp hydrolase assay |
US8652785B2 (en) * | 2008-12-04 | 2014-02-18 | Sanofi | Method of screening a modulator of endothelial NO synthase comprising the use of heme binding protein 1 |
RU2526575C2 (ru) * | 2012-11-02 | 2014-08-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ повышения иммуносупрессивных свойств мезенхимальных стромальных клеток жировой ткани |
EP3204509B1 (en) | 2014-10-08 | 2019-07-10 | Promega Corporation | Bioluminescent succinate detection assay |
CN107802826B (zh) * | 2017-10-26 | 2020-02-18 | 首都医科大学宣武医院 | eNOS突变体在促进血管生成中的应用 |
CN116790603B (zh) * | 2023-08-18 | 2023-10-31 | 成都中科奥格生物科技有限公司 | 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5498539A (en) * | 1992-07-02 | 1996-03-12 | Daiichi Pharmaceutical Co., Ltd. | Bovine endothelial nitric oxide synthase nucleic acids |
US5658565A (en) * | 1994-06-24 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inducible nitric oxide synthase gene for treatment of disease |
DE4411402A1 (de) * | 1994-03-31 | 1995-10-05 | Juergen Schrader | DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen |
FR2722507B1 (fr) * | 1994-07-12 | 1996-08-14 | Rhone Poulenc Rorer Sa | Adenovirus comportant un gene codant pour une no synthase |
US5968983A (en) * | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
US5837534A (en) * | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
JP2002528390A (ja) * | 1998-10-02 | 2002-09-03 | セント エリザベス メディカル センター, インコーポレイテッド | 細胞の生存を増強するためのakt組成物 |
DE60039677D1 (de) * | 1999-03-19 | 2008-09-11 | Aventis Pharma Inc | Akt-3 nukleinsäure, polypeptide und deren verwendung |
CN100357433C (zh) * | 1999-04-16 | 2007-12-26 | 耶鲁大学 | 可用于基因治疗和治疗性筛选的eNOS突变 |
CZ20014444A3 (cs) * | 1999-06-11 | 2002-05-15 | Aventis Pharmaceuticals Products Inc. | Protein Akt pro pouľití k indukci exprese VEGF |
-
2000
- 2000-04-14 CN CNB008063257A patent/CN100357433C/zh not_active Expired - Fee Related
- 2000-04-14 AU AU42378/00A patent/AU774010B2/en not_active Ceased
- 2000-04-14 SK SK1469-2001A patent/SK14692001A3/sk not_active Application Discontinuation
- 2000-04-14 JP JP2000611751A patent/JP2002541829A/ja active Pending
- 2000-04-14 PL PL00351087A patent/PL351087A1/xx not_active Application Discontinuation
- 2000-04-14 EE EEP200100538A patent/EE200100538A/xx unknown
- 2000-04-14 BR BR0009805-1A patent/BR0009805A/pt not_active IP Right Cessation
- 2000-04-14 RU RU2001130901/15A patent/RU2257226C2/ru not_active IP Right Cessation
- 2000-04-14 UA UA2001107249A patent/UA76939C2/uk unknown
- 2000-04-14 NZ NZ514305A patent/NZ514305A/xx unknown
- 2000-04-14 CZ CZ20013427A patent/CZ20013427A3/cs unknown
- 2000-04-14 KR KR1020017013218A patent/KR100737945B1/ko not_active IP Right Cessation
- 2000-04-14 HU HU0200799A patent/HUP0200799A3/hu unknown
- 2000-04-14 MX MXPA01010459A patent/MXPA01010459A/es not_active Application Discontinuation
- 2000-04-14 EP EP00922148A patent/EP1178722A4/en not_active Withdrawn
- 2000-04-14 YU YU73301A patent/YU73301A/sh unknown
- 2000-04-14 IL IL14576000A patent/IL145760A0/xx unknown
- 2000-04-14 WO PCT/US2000/009913 patent/WO2000062605A1/en active Application Filing
- 2000-04-14 CA CA002369764A patent/CA2369764A1/en not_active Abandoned
-
2001
- 2001-09-20 US US09/956,699 patent/US6900038B2/en not_active Expired - Lifetime
- 2001-10-15 NO NO20015008A patent/NO20015008L/no not_active Application Discontinuation
- 2001-10-15 ZA ZA200108463A patent/ZA200108463B/en unknown
- 2001-10-26 BG BG106051A patent/BG106051A/xx unknown
- 2001-10-29 HR HR20010797A patent/HRP20010797A2/hr not_active Application Discontinuation
-
2002
- 2002-10-28 HK HK02107786.1A patent/HK1046081B/zh not_active IP Right Cessation
-
2004
- 2004-07-12 US US10/889,121 patent/US20040253685A1/en not_active Abandoned
- 2004-09-10 AU AU2004210533A patent/AU2004210533A1/en not_active Abandoned
-
2008
- 2008-12-09 US US12/316,128 patent/US7888089B2/en not_active Expired - Fee Related
-
2011
- 2011-02-14 US US13/026,973 patent/US20110173711A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7888089B2 (en) | eNOS mutations useful for gene therapy and therapeutic screening | |
AU701345B2 (en) | Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis | |
US6165977A (en) | Isozyme-specific activators of protein kinase C methods and compositions | |
AU2004204815B2 (en) | Method for in vivo regulation of cardiac muscle contractility | |
US5498539A (en) | Bovine endothelial nitric oxide synthase nucleic acids | |
CA2369826C (en) | Therapy of cardiac insufficiency | |
US6451759B1 (en) | Noncleavable Fas ligand | |
US20040005684A1 (en) | Targeting proteins to deliver therapeutic or diagnostic reagents | |
US20030228285A1 (en) | Bipartite T-cell factor (Tcf)-responsive promoter | |
JPH11123086A (ja) | セリン−トレオニンプロテインキナーゼ(h−sgk2) | |
JP2002511764A (ja) | Pakキナーゼ遺伝子およびポリペプチドならびにそれらの使用方法 | |
KR100737947B1 (ko) | 유전자 치료 및 치료 스크리닝에 유용한 eNOS 돌연변이 | |
AU746190B2 (en) | Heart and skeleton muscle specific nucleic acid, the production and use thereof | |
AU2008201816A1 (en) | eNOS mutations useful for gene therapy and therapeutic screening | |
US20050014692A1 (en) | Lactate dehydrogenase as a novel target and reagent for diabetes therapy | |
JPH11505421A (ja) | ヒトウリジンジホスフェートガラクトース−4−エピメラーゼ | |
JP2002369684A (ja) | ヒトウリジンジホスフェートガラクトース−4−エピメラーゼ | |
WO2001040283A1 (fr) | NOUVEAU POLYPEPTIDE, ACYL-CoA DESHYDROGENASE HUMAINE 11 CONTENANT UN DOMAINE DE LIAISON ATP/GTP, ET POLYNUCLEOTIDE CODANT POUR CE POLYPEPTIDE |